DHG Pharmaceutical JSC (DHG) fair value: what the stock is really worth
As of Nov 9, 2026: fair value (intrinsic value) of DHG Pharmaceutical JSC stock VND 101,248, price VND 84,400, upside +20.0%, quality 86 out of 100. Rating: undervalued. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.
69 individual criteria per stock, every one traceableSee the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year. As of Nov 8, 2026.
How to read this chart
60‑month range 62,771 VND – 113,150 VND · fair‑value band 72,344 VND – 138,847 VND · the 84,400 VND price screens below the 101,248 VND fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). As of Nov 8, 2026.
Follow DHG Pharmaceutical JSC in your weekly email
Every Wednesday you see whether DHG Pharmaceutical JSC is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
DHG Pharmaceutical Joint Stock Company, together with its subsidiaries, engages in the manufacture and sale of pharmaceutical products in Vietnam.
Show moreShow less
The company offers antibiotic, analgesic and antipyretic, respiratory, nutrition, musculoskeletal, gastrointestinal and hepatobiliary, nervous and ophthalmic, cardiovascular and diabetic, dermatology, and beauty care products.
It also manufactures and trades in health food, dietary and consumer health supplements, and pharmaceuticals cosmetic products. It also exports its products. DHG Pharmaceutical Joint Stock Company was founded in 1974 and is headquartered in Can Tho, Vietnam.
DHG Pharmaceutical Joint Stock Company is a subsidiary of Taisho Pharmaceutical Co., Ltd.
Stock analysis
DHG Pharmaceutical JSC (DHG) currently trades at 84,400 VND, while our model-based Fair Value estimate is 101,248 VND, implying the stock looks roughly 17% undervalued today.
Show more
Valuation
Bull case: the Growth Earnings group reads highest at a median of 125,207 VND per share, and 20 of the 26 models we run sit above the 84,400 VND price.
Bear case: the Asset-Based group reads lowest at 22,212 VND, and 6 of the 26 models stay below the price. Data coverage for this calculation is high.
Scenario range: 72,344 VND (bear) to 138,847 VND (bull), the price of 84,400 VND sits inside it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 86/100 (high quality), in the Healthcare sector.
Healthy Growth: Revenue growth appears healthy and is supported by profitability and cash-flow quality.
DHG Pharmaceutical JSC reported revenue of 5.3T VND in FY2025 versus 4.0T VND in FY2021, a compound +7.1%/yr. Reported net income was 852B VND in FY2025, compounding +2.3%/yr from FY2021.
Key figures
Market cap 11.0T VND (≈ $431M) Small · P/E ratio 11.3 · P/S ratio 2.05 · EPS (TTM) 7,443 VND · Dividend yield 5.9% · Net margin 16.0% · Return on equity 22.7% · Return on assets (EBIT) 17.9% (5-year average).
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 72 out of 100 (low confidence).
What moves the price
The share trades about 17% below its 52-week high and 2% above its 52-week low, currently below its 200-day average.
For context, the median of 10 Healthcare peers we cover trades at −27% fair-value upside, at 20%, DHG screens cheaper than that median.
Fair Value models
Bear72,344 VNDFair Value 101,248 VNDBull138,847 VND
Price 84,400 VND · Upside +20.0%
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above starts from their evidence-weighted blend, not from a single model. In cyclical trough or peak years, after dilution or a stock split it is adjusted afterwards, so it can sit above or below the models. Based on fiscal year 2025 figures (about 10 months old). Earnings retained since then (2,095 VND per share) are deliberately not added.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds.Coverage ⓘCoverage = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.84/100
Revenue growth appears healthy and is supported by profitability and cash-flow quality.
Revenue growth 1 year
+7.8%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+4.0%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+7.0%
Start year 2020 (pandemic)
Revenue growth 6 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+5.2%
’19
’20
’21
’22
’23
’24
’25
What shareholders gained per year (last 5 years), in VND ⓘWhat the business itself delivers per year: earnings growth per share plus the dividend yield. This is what you get IF the market keeps valuing the stock the same way: it contains no assumption about the market changing its mind. Computed per share, so buybacks count and a merger does not pass as growth. For a company that pays no dividend it is pure earnings growth per share. Period: earnings growth per share as CAGR over the last 5 reported fiscal years (annual statements), plus the current dividend yield. The start value is the median of the three years around the start, so a single crisis year (a pandemic or a write-down) does not distort the rate. Measured in VND: this currency has depreciated against the euro and dollar over the long run, so part of the nominal rate is currency erosion that never reaches a EUR/USD investor.
+8.8%
Earnings growth per share plus dividend.
Earnings per share, growth per year+2.9%
Dividend (yield on the price)5.9%
Profit margin 2020 to 2025 ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.21% → 18%
Growth Forecast
Little optimism in the price
The price assumes less growth than the company has delivered so far.
What the price assumes ⓘThis turns our valuation around: instead of asking what the share is worth, it asks what growth the current price requires. It uses the cash the company keeps after all spending (free cash flow), the same discount rate as our models, five years of growth, then slowing evenly to 2 % a year by year ten. Compared with the analysts' sales forecasts extended to the same five years (at least three analysts, for context only, it does not enter the Fair Value): within 3 percentage points counts as "in line" (amber), below that little optimism (green), above that a lot of optimism (red).
+2.6%
Yearly growth needed for the next five years to justify today's price.
What forecasts expect
n/a
No analyst forecast available.
After inflation (Vietnam: IMF forecast 4.1% a year to 2030, 3.1% from 2016 to 2025) that is about −1.4% a year for the price.
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Drug Manufacturers - Specialty & Generic · 549 stocks
Beats the industry median on 11/13 measures
Overall it ranks above its industry peers.
Valuation
Quality Score86 · Top 25%
Fair Value upside+21.3% · Above median
Profitability
Return on equity (12 months)22.7% · Top 25%
Return on assets16.5% · Top 25%
Net margin (12 months)16.0% · Top 25%
Operating margin (12 months)10.9% · Above median
Growth and dividend
Revenue growth (quarter YoY)−10.7% · Bottom 25%
Dividend yield (12 months)5.9% · Top 25%
Valuation Multiplesvs Drug Manufacturers - Specialty & Generic median · lower = cheaper
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Is DHG Pharmaceutical JSC (DHG) overvalued or undervalued?
As of Nov 8, 2026, our model estimates a fair value of 101,248 VND versus a price of 84,400 VND, about +20% upside (undervalued).
What is the fair value of DHG?
Our model-based fair value for DHG Pharmaceutical JSC is 101,248 VND (as of Nov 8, 2026), built from audited fundamentals. The current price: 84,400 VND.
What is the quality score of DHG?
DHG Pharmaceutical JSC has a Quality Score of 86/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for DHG Pharmaceutical JSC (DHG)?
Our model-based price target is the fair value of 101,248 VND (as of Nov 8, 2026) from 26 valuation models. Cautious scenario 72,344 VND, optimistic scenario 138,847 VND. It is a calculation from audited fundamentals, not an analyst target.
What is the DHG Pharmaceutical JSC stock forecast for 2026?
Our models put fair value at 101,248 VND, about +20% upside versus a price of 84,400 VND (undervalued). Cautious scenario 72,344 VND, optimistic scenario 138,847 VND. The calculation is refreshed regularly with new filings.
What is the revenue of DHG Pharmaceutical JSC (DHG)?
DHG Pharmaceutical JSC reported trailing-twelve-month revenue of about 5.3T VND (latest available figure, as of Nov 8, 2026).
Does DHG Pharmaceutical JSC pay a dividend?
DHG Pharmaceutical JSC currently shows a dividend yield of 5.92% relative to its recent price (as of Nov 8, 2026).
How much is the dividend of DHG Pharmaceutical JSC (DHG) and when is the ex-dividend date?
DHG Pharmaceutical JSC pays a dividend of 5,000 VND per share a year, a dividend yield of 5.9%. The last ex-dividend date was Sep 14, 2026. A dividend has been paid every year since at least 2008. The payout ratio is 67.2% of earnings. Free cash flow covers the dividend 1.81 times. Our assessment: Sustainable. Payout and cash coverage both look sustainable.
What growth is priced into DHG Pharmaceutical JSC (DHG)?
For today's price to be fair in a discounted-cash-flow model, DHG Pharmaceutical JSC would have to grow free cash flow by +2.6 % per year for five years (discount rate 13.4 %, then slowing evenly to 2 % perpetual growth by year ten). Over the last 5 years revenue grew +7.0 % per year. As of Nov 8, 2026.
What discount rate (WACC) does the fair value of DHG use?
Our models discount DHG Pharmaceutical JSC at 13.4 %: a base by market capitalisation (small), damped by beta 0.25, country premium for Vietnam. The same rate applies in all 26 models.
What is a reverse DCF?
A reverse DCF turns the usual calculation around. Instead of deriving a value from assumptions, it takes today's price as given and asks: what free-cash-flow growth would a company have to deliver for exactly this price to be fair? The result is not a forecast but the expectation already priced in. For DHG Pharmaceutical JSC that is +2.6 % per year for five years, then slowing evenly to 2 % by year ten, using the same discount rate (13.4 %) and the same formula as our fair value.
How much growth has DHG Pharmaceutical JSC (DHG) delivered so far?
Over the past 5 years revenue at DHG Pharmaceutical JSC grew +7.0 % a year. The price currently implies free-cash-flow growth of +2.6 % per year. Comparing the two shows how much confidence is in the price: if it demands more than has been delivered, the business has to accelerate for the maths to work.
How fast is the sector of DHG Pharmaceutical JSC (DHG) growing?
The median revenue growth in the sector is +1.7 % a year. That is the yardstick for the growth priced into DHG Pharmaceutical JSC (+2.6 % per year): it shows whether the expectation is within the usual range or beyond it.
What is the free cash flow yield of DHG Pharmaceutical JSC (DHG)?
The free-cash-flow yield on the price is 10.71 %: that much free cash flow DHG Pharmaceutical JSC produces per unit of market value. When it exceeds the discount rate of our models (13.4 %), the business already earns more than its cost of capital demands, and the price needs little additional growth.
What is the intrinsic value of DHG Pharmaceutical JSC (DHG)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For DHG Pharmaceutical JSC it is 101,248 VND per share (as of Nov 8, 2026), against a price of 84,400 VND. It is the blended result of 26 valuation models in 8 families (DCF Models, Earnings-Based, Dividend Discount, Multiples, Asset-Based, Growth DCF, Economic Profit, Growth Earnings).
Is DHG Pharmaceutical JSC stock overvalued or undervalued in 2026?
As of Nov 8, 2026, DHG trades below its calculated fair value: price 84,400 VND, fair value 101,248 VND, a gap of about +20% (undervalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of DHG?
No. The price is what the market pays today (84,400 VND); the fair value is what the company's own numbers justify (101,248 VND). For DHG Pharmaceutical JSC the two are 16,848 VND per share apart. That gap is exactly why we show both numbers side by side.
How much is DHG Pharmaceutical JSC worth?
The market values DHG Pharmaceutical JSC at about 11.0T VND (market capitalisation, as of Nov 8, 2026). Per share that is 84,400 VND; our models calculate a fair value of 101,248 VND per share.
What do the bullish and bearish scenarios say about DHG?
Our models span a range for DHG Pharmaceutical JSC: cautious scenario 72,344 VND, base 101,248 VND, optimistic 138,847 VND per share (as of Nov 8, 2026, price 84,400 VND). The range comes from different growth and margin assumptions, not from analyst opinions.
What is the P/E ratio of DHG?
DHG Pharmaceutical JSC trades at a price-to-earnings ratio of 11.3 (as of Nov 8, 2026). A P/E on its own says little: it compares the price with ONE year of profit, while our fair value of 101,248 VND is built from several models across several years. Median P/E at fiscal year-end, 7 fiscal years (2019 to 2025), reported earnings, FY2025 ex one-offs: 17.1. Other multiples: P/B 2.6, P/S 2.0, EV/EBITDA 9.9.
How solid is the balance sheet of DHG Pharmaceutical JSC (DHG)?
Balance-sheet figures for DHG Pharmaceutical JSC (as of Nov 8, 2026): return on equity 22.7%. They feed the Quality Score of 86/100, which measures business quality independently of the share price.
How far is DHG from its 52-week high?
DHG Pharmaceutical JSC trades at 84,400 VND, about 17% below its 52-week high of 101,655 VND and 2% above the low of 82,500 VND (as of Nov 9, 2026). Distance from the high says nothing about value: that is what the fair value of 101,248 VND is for.
Which stocks are comparable to DHG Pharmaceutical JSC?
From the same area (Healthcare) we also value Merck KGaA, Takeda Pharmaceutical Company, Galderma Group, Teva Pharmaceutical Industries Limited, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is DHG Pharmaceutical JSC stock attractive at the current price?
The data as of Nov 8, 2026: price 84,400 VND, calculated fair value 101,248 VND (+20%), Quality Score 86/100, from 26 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of DHG calculated?
We run DHG Pharmaceutical JSC through 26 models from 8 families: DCF Models, Earnings-Based, Dividend Discount, Multiples, Asset-Based, Growth DCF, Economic Profit, Growth Earnings. Every model gets the same audited fundamentals; the fair value of 101,248 VND builds on their evidence-weighted average, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 13.3% above its aggregate fair value. DHG Pharmaceutical JSC currently trades 17% below its own fair value, and the market average says nothing about that. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of DHG Pharmaceutical JSC (DHG)?
The closing price on Nov 9, 2026 was 84,400 VND. Our model-based fair value is 101,248 VND, about +20% upside (undervalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with DHG Pharmaceutical JSC right now?
A fairly wide model range (72,344 VND to 138,847 VND) leaves room in how you read the outcome. The price sits in the lower half of our model range, the side with the larger margin of safety. The data supports the verdict: every model runs on fully documented inputs.
Key figures of DHG Pharmaceutical JSC
How large is the market capitalisation of DHG Pharmaceutical JSC (DHG)?
The market capitalisation of DHG Pharmaceutical JSC is 11.0T VND (≈ $431M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of DHG Pharmaceutical JSC (DHG)?
The price-to-sales ratio of DHG Pharmaceutical JSC is 2.05 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of DHG Pharmaceutical JSC (DHG)?
Earnings per share at DHG Pharmaceutical JSC are 7,443 VND (price ÷ EPS = P/E 11.3). Earnings per share over the last twelve months: total profit spread across every single share.
What is the dividend yield of DHG Pharmaceutical JSC (DHG)?
The dividend yield of DHG Pharmaceutical JSC is 5.9% (payout 67.2%). Yearly dividend relative to the share price. 3% pays 3 per 100 invested. Below: how much of profit is used for it.
What is the net margin of DHG Pharmaceutical JSC (DHG)?
The net margin of DHG Pharmaceutical JSC is 16.0% (last twelve months). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of DHG Pharmaceutical JSC (DHG)?
The return on equity (ROE) of DHG Pharmaceutical JSC is 22.7% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of DHG Pharmaceutical JSC (DHG)?
On an EBIT basis the return on assets of DHG Pharmaceutical JSC is 17.9% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of DHG Pharmaceutical JSC (DHG)?
The operating margin of DHG Pharmaceutical JSC is 10.9% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at DHG Pharmaceutical JSC (DHG)?
Revenue at DHG Pharmaceutical JSC is growing −10.7% versus a year earlier (3y avg +4.0%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at DHG Pharmaceutical JSC (DHG)?
Earnings per share at DHG Pharmaceutical JSC are growing −53.0% versus a year earlier. How much earnings per share grew versus a year earlier.
How much net debt does DHG Pharmaceutical JSC (DHG) carry?
The net debt of DHG Pharmaceutical JSC is 587B VND (fiscal year 2024, ≈ 0.5 yrs of FCF). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed
Watch DHG Pharmaceutical JSC in the live analysis
One click puts DHG Pharmaceutical JSC on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.
Broad data
Nov 8, 2026